Nadia Raban

661 total citations
17 papers, 145 citations indexed

About

Nadia Raban is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Nadia Raban has authored 17 papers receiving a total of 145 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Reproductive Medicine and 4 papers in Molecular Biology. Recurrent topics in Nadia Raban's work include Ovarian cancer diagnosis and treatment (10 papers), Lung Cancer Research Studies (3 papers) and PARP inhibition in cancer therapy (3 papers). Nadia Raban is often cited by papers focused on Ovarian cancer diagnosis and treatment (10 papers), Lung Cancer Research Studies (3 papers) and PARP inhibition in cancer therapy (3 papers). Nadia Raban collaborates with scholars based in France, Spain and Italy. Nadia Raban's co-authors include J. P. Lamagnere, Guillaume Cartron, Arnaud Petit, Claude Linassier, Martine Delain, Lotfi Benboubker, M. Georget, Philippe Colombat, Carole Barin and G. Calais and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Nadia Raban

15 papers receiving 139 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nadia Raban France 7 62 47 43 32 23 17 145
Erik Asmus United States 6 100 1.6× 43 0.9× 39 0.9× 18 0.6× 17 0.7× 9 179
Bruno Chiurazzi Italy 5 50 0.8× 35 0.7× 31 0.7× 11 0.3× 23 1.0× 12 118
Po-Nan Wang Taiwan 6 26 0.4× 67 1.4× 14 0.3× 19 0.6× 69 3.0× 10 126
Samantha Tippen United States 5 20 0.3× 27 0.6× 53 1.2× 35 1.1× 10 0.4× 9 149
Anmol Baranwal United States 6 26 0.4× 29 0.6× 17 0.4× 130 4.1× 19 0.8× 24 196
Ramya Varadarajan United States 5 57 0.9× 17 0.4× 9 0.2× 54 1.7× 7 0.3× 12 148
Ana Santaballa Bertrán Spain 5 30 0.5× 40 0.9× 18 0.4× 7 0.2× 15 0.7× 11 81
Heather Lloyd-Jones United Kingdom 3 31 0.5× 16 0.3× 14 0.3× 16 0.5× 16 0.7× 3 223
Riccardo Rosso Italy 4 79 1.3× 42 0.9× 11 0.3× 3 0.1× 13 0.6× 5 128
Wajeeha Aiman United States 6 31 0.5× 7 0.1× 29 0.7× 54 1.7× 4 0.2× 34 132

Countries citing papers authored by Nadia Raban

Since Specialization
Citations

This map shows the geographic impact of Nadia Raban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Raban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Raban more than expected).

Fields of papers citing papers by Nadia Raban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Raban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Raban. The network helps show where Nadia Raban may publish in the future.

Co-authorship network of co-authors of Nadia Raban

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Raban. A scholar is included among the top collaborators of Nadia Raban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Raban. Nadia Raban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Cătană, Andreea, Gaëtan De Rauglaudre, Nadia Raban, et al.. (2023). 793P Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO). Annals of Oncology. 34. S532–S532. 1 indexed citations
2.
Blanc‐Durand, Félix, Elisa Yaniz‐Galende, Catherine Genestie, et al.. (2022). Immune tumor microenvironnement (iTME) post-neoadjuvant chemotherapy, beyond PD-L1: Novel immune targets in ovarian cancer, data from the CHIVA trial, a GINECO/GINEGEPS study.. Journal of Clinical Oncology. 40(16_suppl). 5554–5554. 1 indexed citations
3.
4.
Blanc‐Durand, Félix, Catherine Genestie, Étienne Rouleau, et al.. (2021). Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.. Journal of Clinical Oncology. 39(15_suppl). 5513–5513. 10 indexed citations
5.
6.
7.
Ferron, Gwénaël, Gaëtan De Rauglaudre, Pierre Combe, et al.. (2019). Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.. Journal of Clinical Oncology. 37(15_suppl). 5512–5512. 11 indexed citations
8.
Tod, Michel, Olivier Colomban, Isabelle Laure Ray-Coquard, et al.. (2019). Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: Data from the randomized CHIVA trial (a GINECO-GCIG study). Annals of Oncology. 30. v783–v784. 1 indexed citations
9.
Lelièvre, Loïc, Philippe Clézardin, Laurent Magaud, et al.. (2018). Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer. 18(6). e1311–e1321. 8 indexed citations
10.
11.
Alexandre, J., Chris Brown, David Coeffic, et al.. (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer. 106(4). 633–637. 27 indexed citations
12.
Kurtz, Jean‐Emmanuel, Gilles Freyer, Florence Joly, et al.. (2012). Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: a GINECO phase I-II trial.. PubMed. 32(3). 1045–9. 8 indexed citations
13.
Migeot, Virginie, Gauthier Bouche, Nadia Raban, et al.. (2011). Who needs a comprehensive geriatric assessment? A French Onco-Geriatric Screening tool (OGS). Journal of Geriatric Oncology. 2(2). 130–136. 14 indexed citations
14.
Tasu, J.P., et al.. (2009). Imagerie des tumeurs endocrines digestives : le point de vue du radiologue. Médecine Nucléaire. 33(11). 695–705.
15.
Migeot, Virginie, Gauthier Bouche, Nadia Raban, et al.. (2008). Validation of a French screening tool to identify older patients needing a Comprehensive Geriatric Assessment in the management of their cancer. Critical Reviews in Oncology/Hematology. 68. S30–S30. 1 indexed citations
16.
Linassier, Claude, Carole Barin, G. Calais, et al.. (2000). Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Annals of Oncology. 11(10). 1289–1294. 56 indexed citations
17.
Raban, Nadia, Bruno Giraudeau, B Desablens, et al.. (2000). VECP-Bleo regimen as treatment of advanced stage aggressive non-Hodgkin’s Lymphoma in elderly patients a GOELAMS protocol. 42(2-3). 142–148. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erik Asmus Breakdown of academic impact, for papers by Bruno Chiurazzi Breakdown of academic impact, for papers by Po-Nan Wang Breakdown of academic impact, for papers by Samantha Tippen Breakdown of academic impact, for papers by Anmol Baranwal Breakdown of academic impact, for papers by Ramya Varadarajan Breakdown of academic impact, for papers by Ana Santaballa Bertrán Breakdown of academic impact, for papers by Heather Lloyd-Jones Breakdown of academic impact, for papers by Riccardo Rosso Breakdown of academic impact, for papers by Wajeeha Aiman
Rankless by CCL
2026